MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03644cam a2200325 a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-GiCUC |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
210816s2021 ua dh f m 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-GiCUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GiCUC |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| 049 ## - LOCAL HOLDINGS (OCLC) |
|---|
| Holding library |
Deposite |
| 097 ## - Thesis Degree |
|---|
| Thesis Level |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Classification number |
Cai01.19.04.M.Sc.2021.Ka.C |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Karim Mohamed Gaber Mahmoud |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Clinical outcomes of IDA-FLAG protocol and its modifications in relapsed/refractory acute leukemias / |
| Statement of responsibility, etc. |
Karim Mohamed Gaber Mahmoud ; Supervised Mosaad Mahmoud Elgammal , Amira Diyaa Darwish , Ghada Mohamed Elsayed |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
IDA-FLAG {uFE8D}{uFEDF}{uFEE8}{uFE98}{uFE8E}{uFE8B}{uFE9E} {uFE8D}{uFEFB}{uFEDB}{uFEE0}{uFEF4}{uFEE8}{uFEF4}{uFEDC}{uFEF4}{uFE94} {uFEFB}{uFEB3}{uFE98}{uFEA8}{uFEAA}{uFE8D}{uFEE1} {uFE91}{uFEAE}{uFEED}{uFE97}{uFEEE}{uFEDB}{uFEEE}{uFEDD} {uFEED} {uFE97}{uFECC}{uFEAA}{uFEF3}{uFEFC}{uFE97}{uFEEA} {uFED3}ى {uئإ٨ؤ}{uئإؤئ}{uئإإ٠}{uئإإإ}{uئإؤآ}{uئإئ٤}{uئإإ٤}{uئإئ٤}{uئإ٨إ} {uئإ٨ؤ}{uئإؤئ}{uئإء٤}{uئإ٨إ}{uئإء٩}{uئإ٩٣} {uئإ٨ؤ}{uئإؤئ}{uئإإ٤}{uئإءإ}{uئإ٩٧}{uئإء٠}{uئإأأ}{uئإ٩٤} {uئإإؤ} {uئإ٨ؤ}{uئإؤئ}{uئإؤ٠}{uئإئ٤}{uئإءإ} {uئإإ٣}{uئإآ٤}{uئإ٩٨}{uئإء٠}{uئإئ٤}{uئإ٩٢}{uئإ٩٤} {uئإؤئ}{uئإإ٠}{uئإأأ}{uئإئأ}{uئإ٩ؤ} |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Cairo : |
| Name of publisher, distributor, etc. |
Karim Mohamed Gaber Mahmoud , |
| Date of publication, distribution, etc. |
2021 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
84 P. : |
| Other physical details |
charts , facsimiles ; |
| Dimensions |
25cm |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology (Medical) |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Background Patients with relapsed/refractory acute leukemias have poor prognosis and the optimal treatment for these cases is controversial. Many agents have been used to achieve the desired goal of CR before HCST. IDA-FLAG protocol and its modifications are some of the widely used agents in this setting. The aim of this study is to determine the clinical outcomes of adopting such treatment in the National Cancer Institute, Egypt. Methods:This is a retrospective study including relapsed/refractory acute leukemias receiving IDA-FLAG or its modifications who presented to National Cancer Institute , Egypt from December2013 to December2017 . Results Through this period 95 patients were assessed.The median age was about 39 years ranging from 18 to 60 years of age, Performance Status (PS) ranging 1 (34.8%), 2 (51.7%), 3 (13.5%) respectively, with male predominance, 58 (61%), 31 (32.7%), 6 (6.3%) of patients were AML, ALL and MPAL respectively. These patients were further classified to high risk 16 patients (16.8%), intermediate 66 patients (69.5%), low risk 13 patients (13.7%) respectively according to their initial cytogenetic and molecular assay. CR/CRi accounted for nearly 32.7%, Death accounted for 34.7%, refractory disease still after FLAG-IDA in 24.2 %. 10 patients (10.5%) were referred to allo-SCT and Overall survival ranged from 0.03 months to 67.5 months with a median of 2.01 months.Cumulative overall survival was 42.1% at 3 months and 24.2 % at 6 months and only 2 patients remained alive. Toxicity profiles were variable but G3-G4 hematological toxicity almost occurred in all patients. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Additional physical form available note |
Issued also as CD |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Clinical outcomes of IDA-FLAG protocol |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Idarubicin-Fludarabine-High dose Cytarabine GCSF (IDA-FLAG) |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Leukemias |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Amira Diyaa Darwish , |
| Relator term |
|
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ghada Mohamed Elsayed , |
| Relator term |
|
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Mosaad Mahmoud Elgammal , |
| Relator term |
|
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Nazla |
| Reviser |
Revisor |
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Shimaa |
| Reviser |
Cataloger |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
